Arrowhead Pharmaceuticals Inc (ARWR)
Debt-to-equity ratio
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 393,183 | — | — | — | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 185,444 | 330,547 | 483,794 | 160,407 | 271,343 | 364,830 | 446,772 | 377,039 | 398,520 | 453,927 | 452,266 | 372,560 | 408,822 | 436,890 | 445,549 | 454,472 | 461,779 | 493,140 | 494,119 | 500,084 |
| Debt-to-equity ratio | 2.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
September 30, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $393,183K ÷ $185,444K
= 2.12
The debt-to-equity ratio of Arrowhead Pharmaceuticals Inc has shown a significant increase in the most recent period, reaching 2.12 as of September 30, 2024. This marks a notable shift from previous periods where the ratio was reported as 0.00, indicating either the incurrence of debt or a decrease in equity relative to debt. A debt-to-equity ratio of 2.12 suggests that the company's level of debt is more than twice the size of its equity, which may raise concerns about the firm's financial leverage and ability to meet its debt obligations. Further analysis and monitoring of Arrowhead Pharmaceuticals Inc's financial health and capital structure would be advisable to assess the impact of this development on the company's overall financial stability.
Peer comparison
Sep 30, 2024